Euroasian journal of hepato-gastroenterology

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  14 (2024)
Volume  13 (2023)
Volume  12 (2022)
Volume  11 (2021)
Volume  10 (2020)
Volume  9 (2019)
Volume  8 (2018)
Volume  7 (2017)
Volume  6 (2016)
Volume  5 (2015)
Volume  4 (2014)
Volume  3 (2013)
Volume  2 (2012)
Volume  1 (2011)
Related articles

VOLUME 14 , ISSUE 2 ( July-December, 2024 ) > List of Articles

Original Article

Comparison of Clinical Features of HBV and HDV Coinfection with HBV Monoinfection: A Study from the Developing World

Zain Majid, Ghazi Abrar, Salman Ahsam, Danish Kumar, Raja Taha Yaseen, Abbas Ali Tasneem, Syed Mudassir Laeeq, Nasir Luck

Keywords : Developing word, Entecavir, Hepatitis B mono-infection, Hepatitis B and D co-infection, Pakistan, Pegylated interferon

Citation Information : Majid Z, Abrar G, Ahsam S, Kumar D, Yaseen RT, Tasneem AA, Laeeq SM, Luck N. Comparison of Clinical Features of HBV and HDV Coinfection with HBV Monoinfection: A Study from the Developing World. Euroasian J Hepatogastroenterol 2024; 14 (2):151-155.

DOI: 10.5005/jp-journals-10018-1441

License: CC BY-NC 4.0

Published Online: 27-12-2024

Copyright Statement:  Copyright © 2024; The Author(s).


Abstract

Hepatitis B infection remains a significant global health concern, with hepatitis D co-infection observed in approximately 5% of the patients. Treatment options for hepatitis D are currently limited, with most therapies awaiting approval by the FDA. However, there is a lack of comprehensive data on the prevalence and clinical presentation of patients with hepatitis B and D coinfection, particularly in Pakistan. In this study, we aimed to compare demographic characteristics, clinical presentations, laboratory, and endoscopic parameters along with the different treatment options between patients with hepatitis B monoinfection and those with hepatitis B and D coinfection.

PDF Share
  1. [Internet]. [cited 2024 Feb 6]. Available from: https://www.uptodate.com/contents/epidemiology-transmission-and-prevention-of-hepatitis-b-virus-infection.
  2. World Health Organization: WHO. Hepatitis D. [(accessed on 13 November 2023)] Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-d [Internet].
  3. Stockdale AJ, Kreuels B, Henrion MYR, et al. The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis. J Hepatol 2020;73:523–532. DOI: 10.1016/j.jhep.2020.04.008.
  4. Alfaiate D, Dény P, Durantel D. Hepatitis delta virus: From biological and medical aspects to current and investigational therapeutic options. Antiviral Res 2015;122:112–129. DOI: 10.1016/j.antiviral.2015.08.009.
  5. World Health Organization. Hepatitis B. [(accessed on 13 November 2023)]; Available online: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b#:~:text=WHO%20estimates%20that%20296%20million,carcinoma%20(primary%20liver%20cancer).
  6. [Internet] [cited 2024 Feb 6]. Available from: https://www.uptodate.com/contents/epidemiology-transmission-and-prevention-of-hepatitis-b-virus-infection [Internet] [cited 2024 Feb 6].
  7. MacLachlan JH, Cowie BC. Hepatitis B virus epidemiology. Cold Spring Harb. Perspect Med 2015;5:a021410. DOI: 10.1101/cshperspect.a021410.
  8. Niro GA, Ferro A, Cicerchia F, et al. Hepatitis delta virus: From infection to new therapeutic strategies. World J Gastroenterol 2021;27:3530–3542. DOI: 10.3748/wjg.v27.i24.3530.
  9. Sellier PO, Maylin S, Brichler S, et al. Hepatitis B virus-Hepatitis D virus mother-to-child co-transmission: A retrospective study in a developed country. Liver Int 2018;38:611–618. DOI: 10.1111/liv.1355.
  10. Stockdale AJ, Kreuels B, Henrion MYR, et al. The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis. J Hepatol 2020;73:523–532. DOI: 10.1016/j.jhep.2020.04.008.
  11. Liang TJ. Hepatitis B: The virus and disease. Hepatology 2009;49:S13–S21. DOI: 10.1002/hep.22881.
  12. Abbas Z. Hepatitis D in Pakistan. J Coll Physicians Surg Pak 2012;22(9):547–548. PMID: 22980605.
  13. Pujol F, Jaspe RC, Loureiro CL, et al. Hepatitis B virus American genotypes: Pathogenic variants? Clin Res Hepatol Gastroenterol 2020;44:825–835. DOI: 10.1016/j.clinre.2020.04.01.
  14. Radjef N, Gordien E, Ivaniushina V, et al. Molecular phylogenetic analyses indicate a wide and ancient radiation of African hepatitis delta virus, suggesting a deltavirus genus of at least seven major clades. J Virol 2004;78(5):2537–2544. DOI: 10.1128/JVI.78.5.2537-2544.2004.
  15. Ali M, Idrees M, Ali L, et al. Hepatitis B virus in Pakistan: A systematic review of prevalence, risk factors, awareness status and genotypes. Virol J 2011;8:102. DOI: 10.1186/1743-422X-8-102.
  16. Negro F. Hepatitis D virus coinfection and superinfection. Cold Spring Harb Perspec. Med 2014;4:a021550. DOI: 10.1101/cshperspect.a021550.
  17. Hirzel C, Wandeler G, Owczarek M, et al. Molecular epidemiology of hepatitis B virus infection in Switzerland: A retrospective cohort study. BMC Infect Dis 2015;15:483. DOI: 10.1186/s12879-015-1234-z.
  18. Sheena BS, Hiebert L, Han H, et al. Global, regional, and national burden of hepatitis B, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol Hepatol 2022;7:796–829. DOI: 10.1016/S2468-1253(22)00124-8.
  19. Romeo R. Hepatitis Delta: Natural history and outcome. Clin Liver Dis 2013;2:235–236. DOI: 10.1002/cld.250.
  20. Mohsin S. Hepatitis B virus/Hepatitis D virus (HBV/HDV) co-infection in Pakistan. Open Forum Infect Dis 2016;3:(suppl_1):428. DOI: 10.1093/ofid/ofw172.292.
  21. Seetlani NK, Abbas Z, Raza S, et al. Prevalence of hepatitis D in HBsAg positive patients visiting liver clinics. J Pak Med Assoc 2009;59:434–437. PMID: 19579728.
  22. Elsaid MI, Li Y, John T, et al. Economic and health care burdens of hepatitis delta: A study of commercially insured adults in the United States. Hepatology 2020;72(2):399–411. DOI: 10.1002/hep.31055.
  23. Mumtaz K, Ahmed US, Memon S, et al. Virological and clinical characteristics of hepatitis delta virus in South Asia. Virol J 2011;8:312. DOI: 10.1186/1743-422X-8-312.
  24. European Association for the Study of the Liver; Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017;67:370–398. DOI: 10.1016/j.jhep.2017.03.021.
  25. Deterding K, Wedemeyer H. Beyond pegylated interferon-alpha: New treatments for hepatitis delta. AIDS Rev 2019;21:126–134. DOI: 10.24875/AIDSRev.19000080.
  26. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018;67:1560–1599.
  27. Koh C, Da BL, Glenn JS. HBV/HDV coinfection: A challenge for therapeutics. Clin Liver Dis 2019;23(3):557–572. DOI: 10.1016/j.cld.2019.04.005.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.